- 作者：Caroline Gronnier ; Emilie Bruy¨¨re ; Guillaume Piessen ; Nicolas Briez ; J¨¦rome Bot ; David Buob ; Emmanuelle Leteurtre ; Isabelle Van Seuningen ; Christophe Mariette
- 刊名：Surgery
- 出版年：2013
- 出版时间：November, 2013
- 年：2013
- 卷：154
- 期：5
- 页码：955-967
- 全文大小：1717 K
Background
The mechanisms of esophageal reflux leading to esophageal adenocarcinoma (EA) remain poorly understood. This study appraises critically an operatively induced chronic reflux rat model.Methods
We randomized 108 Sprague-Dawley rats into 2 experimental groups; one was performing esophagoduodenal (ED) anastomosis with or without gastrectomy to induce duodeno-esophageal reflux (DER group; n = 63), and the other involved duodeno-gastro-esophageal reflux (DGER group; n = 45). Control groups included (i) Roux-en-Y esophagojejunal anastomosis, (ii) laparotomy alone, (iii) subtotal gastrectomy to induce duodenogastric reflux (DGR group), and (iv) the same procedure as in the DGER group plus proton pump inhibition (PPI group). The esophagus underwent histologic and molecular analyses.
Results
The prevalence of Barrett's esophagus (BE), dysplasia, and EA in the experimental groups was 41 % , 7 % , and 11 % , respectively. Histologic and molecular analyses in groups DER, DGER, and DGR suggested that BE occurred through de novo intestinal metaplasia and proximal migration of duodenal cells. No distant metastases were identified. The molecular characteristics of both BE and EA were similar to humans. BE was more common, and dysplasia and EA less frequent in the DER group when compared with the DGER group (44 % vs 24 % [P = .038] and 7 % vs 25 % [P = .012], respectively). Compared with the DGER group, carcinogenic sequence occurred less frequently in the PPI-treated group (P = .019).
Conclusion
Despite pathophysiologic differences with humans, the rat model of esophagoduodenostomy reproduces accurately histologic and molecular lesions in the carcinogenetic sequence of BE and allowed us to identify novel, tumor-associated proteins that may be potential biomarkers and new therapeutic targets in EA.